Dangerous Drug Lawsuit Guide

A General Overview of Dangerous and Defective Drug Lawsuits

Dangerous and defective drug lawsuits have developed alongside the expansion of pharmaceutical regulation and modern product liability law in the United States.

The Federal Food, Drug, and Cosmetic Act of 1938 strengthened federal oversight after a toxic drug preparation killed more than 100 people, while the Kefauver-Harris Amendments of 1962 imposed stronger safety, effectiveness, clinical-testing, and manufacturing requirements following the thalidomide tragedy overseas.

These federal protections increased oversight of pharmaceutical manufacturers, but injured patients generally pursue defective drug injury claims through separate state-law product liability and tort causes of action.

Modern cases may allege problems involving a drug’s design, manufacturing process, warnings, labeling, testing, or promotion rather than merely asserting that the medication caused an unwanted side effect.

Some lawsuits focus on contamination, incorrect potency, sterility failures, or other errors introduced during production, while others allege inadequate testing or failure to adequately investigate emerging safety risks.

Claims may also examine what pharmaceutical manufacturers knew about a serious adverse effect, when they learned it, what information they provided to regulatory agencies and healthcare professionals, and whether stronger warnings should have been provided.

When large numbers of patients bring similar claims involving the same medication, federal cases may be consolidated in multidistrict litigation, as has occurred with GLP-1 receptor agonists and Suboxone film product liability claims.

A class action lawsuit is generally less common for personal injury claims because each patient’s medication history, medical condition, causation evidence, and damages may differ substantially.

Common allegations in dangerous and defective drug litigation include:

• Failure to warn: The manufacturer allegedly failed to adequately disclose a serious side effect, contraindication, drug interaction, or monitoring requirement.
• Design defects: The drug’s formulation or risk profile allegedly made it unreasonably dangerous under the applicable state’s product liability law.
• Manufacturing defects: An error in the manufacturing process allegedly caused a particular batch or dose to differ from its intended specifications.
• Inadequate testing: Plaintiffs may allege that a manufacturer failed to adequately investigate or evaluate a safety risk before or after the medication reached the market.
• Failure to respond to safety information: A company allegedly received studies, adverse-event reports, clinical data, or other information indicating a potential risk but failed to take legally required or otherwise appropriate action.
• Inadequate labeling: The prescribing information or patient-facing warnings allegedly failed to clearly communicate a material risk associated with the medication.
• Misleading marketing or promotion: A manufacturer allegedly overstated a medication’s benefits, minimized known risks, or made representations that support a claim under applicable state law.
• Regulatory or quality-control failures: Evidence involving inspections, manufacturing standards, regulatory submissions, recalls, or communications with regulatory agencies may become relevant to the alleged defect or wrongful conduct.

Multidistrict litigation does not convert the participating cases into a single lawsuit; instead, individual claims are coordinated before one federal judge for common pretrial matters such as discovery, expert testimony, and recurring legal issues.

For example, the federal Suboxone MDL was created in part because the cases shared questions concerning alleged dental injuries, the adequacy of product testing, and the sufficiency of warnings, while separate GLP-1 litigation has coordinated claims involving alleged gastrointestinal injuries.

Much like lawsuits involving defective medical devices, pharmaceutical cases may therefore combine centralized discovery and scientific analysis with individualized evidence concerning each patient’s product use, injury, causation, and damages.

Plaintiffs seeking to obtain compensation generally must establish their own legally viable claim even when hundreds or thousands of similar lawsuits are proceeding together.

This process allows injured patients to pursue responsible parties accountable under applicable law while courts manage recurring evidence and legal questions more efficiently.

How Are Dangerous Drug Lawsuits Different From Other Product Liability Claims?

Dangerous drug lawsuits differ from many other product liability claims because medications are subject to extensive federal regulation before and after they reach the market.

Unlike a defective household product or piece of machinery, such drugs may provide significant medical benefits while also carrying serious known risks.

A patient can suffer unexpected harm even when a medication was prescribed for an approved use, which means the existence of an injury alone does not establish that the product was legally defective.

These cases often require detailed review of FDA labeling, clinical data, adverse-event information, prescribing decisions, and communications between pharmaceutical companies and healthcare professionals.

Plaintiffs may also need to address legal issues such as federal preemption and the learned intermediary doctrine, which are particularly important in prescription drug litigation.

Scientific causation can be more difficult to prove because attorneys and experts may need to distinguish the effects of the medication from underlying disease, other treatments, and competing risk factors.

As a result, dangerous drug claims often depend on a combination of product liability law, medical evidence, regulatory history, and drug-specific scientific research.

Who Can File a Dangerous Drug Lawsuit?

A person may qualify to file a dangerous drug lawsuit if they used a medication and developed serious health problems that may be connected to a defect, inadequate warning, manufacturing problem, or other legally actionable conduct.

Injury victims generally need medical documentation of the condition and evidence identifying the medication involved, although the specific requirements depend on the drug, alleged injury, and applicable state law.

Medical professionals and medical experts may play an important role in determining whether the medication is capable of causing the alleged injury and whether it contributed to the individual patient’s condition.

If the patient died from complications allegedly associated with the medication, an estate representative or qualifying family member may be able to pursue a wrongful death or survival claim.

Parents or guardians may also bring claims on behalf of injured minors, subject to state-specific procedural and settlement requirements.

Factors that may be considered when evaluating a claim include:

• Use of the medication: Pharmacy, prescription, insurance, or medical records should generally establish that the patient used the drug at issue and, when relevant, identify the manufacturer, formulation, dosage, or lot.
• A documented injury: The patient should have a diagnosed medical condition or other compensable injury associated with the alleged risk rather than only temporary or expected side effects.
• Timing of the injury: The onset of symptoms or diagnosis should be medically consistent with the period of drug exposure and the type of injury alleged.
• Warning and regulatory history: The date of use may be important when a claim involves a later label change, safety warning, recall, or newly identified risk.
• Medical causation: Records and expert analysis may be needed to evaluate whether the medication caused or contributed to the injury and to address other possible causes.
• Compliance with applicable deadlines: The claim must be filed within the statute of limitations and any applicable statute of repose.
• A legally viable claim: The facts must support a recognized theory such as failure to warn, manufacturing defect, design defect, negligence, misrepresentation, or another claim available under state law.

Not every person who experiences an adverse reaction to a medication will have a viable lawsuit.

A dangerous drugs attorney can review the patient’s medication history, medical records, alleged injury, available scientific evidence, and applicable law to determine whether further investigation is warranted.

Can You File a Lawsuit If the Drug Was Approved by the FDA?

Yes, in some circumstances.

Approval by the U.S. Food and Drug Administration (FDA) does not automatically prevent an injured patient from pursuing a civil claim against a pharmaceutical manufacturer.

FDA approval means the medication satisfied the federal requirements applicable to its marketing at the time of approval, but it does not necessarily resolve whether the manufacturer later provided adequate warnings, complied with manufacturing requirements, or met duties imposed under state law.

A patient who experiences serious injury, physical suffering, or other compensable harm may still have a claim if the evidence supports an actionable defect or wrongful act.

FDA approval can nevertheless have a significant effect on defective drug litigation.

Pharmaceutical companies may raise federal preemption when they contend that federal law prevented them from making the design, labeling, or warning change alleged by the plaintiff.

The outcome can depend on the type of medication, whether it was a brand-name or generic drug, the specific legal theory asserted, and what authority the manufacturer had under federal regulations to modify the product or its labeling.

Can You Sue If the Medication Was Used Off-Label?

Possibly.

Off-label use occurs when a licensed healthcare provider prescribes an FDA-approved medication for a condition, dosage, age group, or method of administration that is not included in the drug’s approved labeling.

Off-label prescribing is common in medical practice and does not, by itself, mean that the provider or pharmaceutical manufacturer acted improperly.

A dangerous drug claim involving off-label use may instead examine what the manufacturer knew about the risks associated with that use, how the medication was promoted, what information was provided to healthcare professionals, and whether the warnings adequately addressed known or reasonably knowable risks.

Depending on state law and the facts of the case, allegations involving misleading promotion, inadequate warnings, misrepresentation, or another product defect may support legal action.

Prescribing records, marketing materials, communications with medical professionals, FDA labeling history, scientific evidence, and expert testimony may all become relevant when determining whether the off-label use contributed to the patient’s injury.

What Are the Main Types of Defective Drug Lawsuits?

Defective drug lawsuits can arise from problems with a medication’s design, manufacturing process, warnings, labeling, or marketing.

The specific legal theories available depend on state law, the type of drug involved, and the conduct that allegedly caused the patient’s injury.

A single case may involve more than one theory and, in some circumstances, multiple parties involved in the development, manufacture, distribution, prescribing, or sale of the medication.

Plaintiffs in some pharmaceutical cases also allege that companies prioritized profits over drug safety by minimizing risks, delaying warnings, or continuing to promote a product despite evidence of potential harm.

Common types of defective drug claims include:

• Design defect: A design-defect claim alleges that the medication’s intended formulation or inherent characteristics made it unreasonably dangerous. Depending on state law, a plaintiff may need to show that the drug’s risks outweighed its benefits, that a safer feasible alternative was available, or that the product failed another applicable product-liability test. These claims can be difficult in prescription drug cases because courts may also consider the medication’s therapeutic benefits, FDA regulation, warnings, and federal-preemption issues.
• Manufacturing defect: A manufacturing-defect claim alleges that a particular batch, lot, dose, or unit departed from the drug’s intended design or manufacturing specifications. Contamination, incorrect potency, foreign material, sterility failures, mislabeling, or packaging errors can potentially cause a severe injury even when the drug’s underlying design is otherwise acceptable. Evidence may include lot information, pharmacy records, recall notices, testing results, manufacturing records, inspection findings, and expert analysis.
• Failure to warn: A failure-to-warn claim alleges that the manufacturer did not adequately communicate a material risk, contraindication, drug interaction, monitoring requirement, or serious adverse effect associated with the medication. A warning may be challenged as incomplete, unclear, delayed, or insufficient in light of information available to the manufacturer. Many states apply the learned intermediary doctrine, under which a prescription drug manufacturer generally directs warnings to the prescribing healthcare professional rather than the patient, although the precise rules and exceptions vary by jurisdiction.
• Misleading marketing or misrepresentation: A claim may allege that a pharmaceutical company overstated a drug’s benefits, minimized known risks, misrepresented scientific findings, promoted uses without adequate support, or failed to disclose material safety information. Depending on the jurisdiction and cause of action, the plaintiff may need to show that the challenged statements or omissions affected the prescribing, purchasing, or treatment decision. Relevant evidence can include advertisements, sales materials, communications with prescribers, internal company records, training materials, study results, and testimony concerning reliance.

Other legal theories may include negligence, negligent misrepresentation, fraud, breach of warranty, consumer-protection claims, or wrongful death.

The same facts can support several causes of action, but each claim has its own elements and defenses under applicable law.

Who Can Be Liable in a Defective Drug Lawsuit?

Potential defendants depend on where the defect arose and who controlled the relevant conduct.

The manufacturer is often the principal defendant, but other entities in the development, production, distribution, prescribing, or dispensing chain may be implicated.

• Brand-name manufacturer: May be responsible for design, labeling, warnings, manufacturing, or promotion, subject to state and federal law.
• Generic manufacturer: May face claims involving manufacturing or labeling, although federal preemption can substantially limit certain theories.
• Active-ingredient or component supplier: May be liable when a contaminated or nonconforming ingredient contributes to the injury.
• Contract manufacturer or testing laboratory: May be responsible for production, sterility, quality-control, or testing failures.
• Distributor or pharmacy: Liability may arise from mishandling, dispensing errors, improper storage, or other independent conduct; seller protections vary by state.
• Prescribing healthcare provider: A separate medical-malpractice claim may exist if prescribing, monitoring, diagnosis, or informed-consent conduct fell below the applicable standard of care.
• Healthcare facility: A hospital or clinic may be liable for medication administration, storage, monitoring, or employee negligence.

Product-liability and medical-malpractice claims involve different duties, defenses, experts, and deadlines.

The same injury may support both, but fault should not be assumed merely because a provider prescribed an FDA-approved medication or a manufacturer supplied it.

What Must Be Proven in a Dangerous Drug Lawsuit?

To succeed in a dangerous drug lawsuit, the plaintiff generally must prove that they used the defendant’s product, that the drug or the manufacturer’s conduct was legally defective or wrongful, that the defect caused the injury, and that compensable damages resulted.

The exact elements depend on the state, the type of medication, and the legal theories asserted against the drug companies involved.

Defective drugs can cause serious injuries or fatalities, but the existence of a bad outcome alone is not enough to prove liability.

Common issues that plaintiffs may need to establish include:

1. Product identification: The plaintiff must show that they used the medication made or supplied by the defendant, which can be especially important when generic versions or multiple manufacturers are involved.
2. Defect or wrongful conduct: The plaintiff must establish a legally actionable problem involving the drug’s design, manufacturing process, warnings, labeling, marketing, or other conduct.
3. General causation: The evidence must support that the medication is capable of causing the type of injury alleged.
4. Specific causation: The plaintiff must show that the medication caused or materially contributed to their individual injury under the applicable legal standard.
5. Warning causation when applicable: Failure to warn claims involve inadequate disclosure of risks and side effects, and some states require proof that an adequate warning would have changed the prescribing, monitoring, dispensing, or treatment decision.
6. Damages: The plaintiff must establish actual losses resulting from the injury, which may include medical expenses, lost income, pain and suffering, disability, or wrongful death damages.

Causation is often one of the most heavily disputed issues in defective drug litigation.

The timing of symptoms may support a claim, but attorneys and medical experts may also consider dosage, duration of use, known risk factors, biological mechanisms, diagnostic findings, and other possible causes of the injury.

Drug companies may challenge whether the medication was capable of causing the condition or whether another medical factor provides a better explanation.

For that reason, plaintiffs typically need both medical documentation and reliable scientific evidence to prove liability.

Evidence in Dangerous Drug Cases

Evidence in dangerous drug litigation operates on both a litigation-wide and individual level, particularly when claims are consolidated in multidistrict litigation or another mass tort proceeding.

Shared evidence may address questions that apply across many cases, such as what pharmaceutical manufacturers knew about a risk, what clinical trials and studies showed, how warnings changed over time, and how the drug was marketed.

Each plaintiff must still establish individual facts concerning product use, diagnosis, timing, causation, and damages.

An experienced attorney can help obtain, preserve, and organize both categories of evidence while coordinating the plaintiff’s individual proof with the broader scientific and corporate record developed in the litigation.

Important evidence may include:

• Prescription and pharmacy records: These can establish the medication used, manufacturer, dosage, fill dates, prescribing provider, and period of exposure.
• Medical records: Treatment records can document the patient’s health before taking the drug, the alleged injury, diagnostic testing, hospitalization, surgery, follow-up care, and long-term prognosis.
• Clinical trials and studies: Clinical trials, epidemiological studies, case reports, pharmacology research, and other scientific literature may help evaluate whether the drug is capable of causing the alleged injury.
• FDA and regulatory records: Label changes, safety communications, recalls, inspection findings, regulatory submissions, and other agency records may provide evidence concerning known risks and the timing of safety actions.
• Drug labeling and medication guides: Historical versions of warnings, prescribing information, contraindications, and patient materials can be important in failure-to-warn claims.
• Internal company documents: Emails, safety analyses, adverse-event reviews, meeting records, testing data, and other materials obtained during discovery may show what a manufacturer knew and how it responded to potential risks.
• Marketing and sales materials: Advertisements, sales presentations, training materials, communications with prescribers, and promotional records may be relevant to allegations involving misleading marketing or inadequate risk disclosure.
• Prescriber testimony and records: A prescribing medical professional may provide evidence about why the medication was selected, what warnings were available, and whether different information would have affected the treatment decision.
• Individual exposure evidence: Pill bottles, packaging, receipts, insurance records, dosage histories, and medication logs can help establish when and how the plaintiff used the product.
• Damages evidence: Medical bills, employment records and wage information (for lost wages), disability documentation, caregiving expenses, and expert assessments may be used to establish the financial and personal consequences of the injury.

How Do FDA Recalls and Safety Warnings Affect a Drug Lawsuit?

An FDA drug recall, safety communication, boxed warning, label change, or manufacturing inspection can provide important evidence in a dangerous drug lawsuit, but regulatory action does not automatically establish civil liability.

A recall may identify a contaminated product, manufacturing problem, incorrect dosage, labeling error, or other defect and can help establish which lots or products were affected and when the problem became known.

The FDA classifies recalls into three categories based on the level of health risk:

• Class I recalls involve a reasonable probability of serious adverse health consequences or death
• Class II recalls involve temporary or medically reversible harm or a remote probability of serious harm
• Class III recalls involve products that are unlikely to cause adverse health consequences.

The FDA may also require a boxed warning, sometimes called a black box warning, when prescription drug labeling must prominently communicate certain serious or potentially life-threatening risks.

A boxed warning may become relevant to questions about what risks were known, when warnings changed, and whether healthcare professionals received adequate safety information.

However, the existence of a warning does not automatically prove that an earlier warning was legally inadequate or that the medication caused a particular patient’s injury.

A drug does not have to be recalled for an injured patient to pursue compensation.

Dangerous drug claims may involve inadequate warnings, previously undisclosed risks, misleading representations, design allegations, or manufacturing defects that never resulted in a recall.

A patient may therefore be able to file a claim even if the medication remained on the market, but the plaintiff must still prove product use, an actionable legal theory, causation, and damages under applicable law.

Patients should not stop taking a prescription medication solely because they learn about a drug recall, warning, or lawsuit.

Depending on the medication and circumstances, abruptly discontinuing treatment can create additional health risks, and FDA advises patients to follow recall instructions and speak with a healthcare professional when they have questions about continuing treatment.

Does an FDA Adverse Event Report Prove a Drug Caused an Injury?

No.

An adverse-event report submitted to the FDA Adverse Event Monitoring System (AEMS), formerly known as the FDA Adverse Event Reporting System (FAERS), documents a medical event that occurred after exposure to a drug but does not establish that the medication caused the event.

Reports may be incomplete, duplicated, unverified, or missing important information about a patient’s medical history, other medications, or alternative causes.

Adverse-event data can still help the FDA and researchers identify potential safety signals that may warrant further investigation, label changes, additional studies, or other regulatory action.

However, the number of reports cannot by itself establish how frequently an injury occurs or prove that one drug is more dangerous than another.

Reliable causation analysis generally considers the broader scientific record, including clinical trials, epidemiological studies, biological mechanisms, medical records, and other evidence relevant to the alleged injury.

What Injuries Can Lead to a Dangerous Drug Lawsuit?

Qualifying injuries depend on the medication and alleged defect.

The injury must be medically documented and sufficiently connected to the drug exposure.

Minor, temporary side effects that were adequately disclosed may not support a viable lawsuit without additional evidence.

Serious alleged injuries may include:

• Heart attack, stroke, blood clots, arrhythmia, or other cardiovascular harm;
• Liver failure, kidney injury, or other organ damage;
• Cancer or other diagnosed diseases allegedly associated with the medication;
• Severe bleeding, gastrointestinal injury, or internal hemorrhage;
• Neurological injury, seizures, movement disorders, or cognitive impairment;
• Severe skin reactions, anaphylaxis, or other immune-mediated injuries;
• Vision loss, hearing damage, or other sensory impairment;
• Birth defects, pregnancy complications, or reproductive injuries;
• Metabolic, endocrine, or bone injuries;
• Addiction, dependence, withdrawal injury, or overdose;
• Permanent disability or disfigurement; and
• Death.

A diagnosis should be evaluated in light of when the patient used the medication, the dose and duration of use, the expected time between exposure and development of the condition, known risk factors, and other possible causes.

Different injuries allegedly associated with the same medication may require different scientific and medical evidence to establish causation.

How Long Do You Have to File a Dangerous Drug Lawsuit?

The deadline to file a dangerous drug lawsuit is controlled by the applicable statute of limitations, and the time available can vary significantly by state and type of claim.

In many jurisdictions, the filing period begins when the injury occurs or when the patient discovers, or reasonably should have discovered, both the injury and its possible connection to the medication.

Several rules can affect when the deadline begins or expires:

• Discovery rule: Some states allow the limitations period to begin when the patient knew or reasonably should have known about the injury and its potential cause.
• Statute of repose: A separate statute may impose an absolute deadline measured from the drug’s sale, manufacture, or another specified event, even if the injury was discovered later.
• Fraudulent concealment: In some circumstances, concealment of material information may toll or extend the filing deadline.
• Minority or incapacity: State law may pause certain filing periods for minors or legally incapacitated individuals, subject to specific exceptions and outside limits.
• Wrongful death: A wrongful death claim may have its own limitations period measured from the patient’s death.
• Medical malpractice: Claims against a prescribing physician, hospital, or other healthcare provider may be governed by separate and sometimes shorter deadlines than claims against pharmaceutical manufacturers.

An FDA warning, label change, safety communication, or drug recall does not automatically determine when the statute of limitations begins.

The relevant date may instead depend on when the patient was injured, when the condition was diagnosed, when a connection to the medication reasonably could have been discovered, and which state’s law applies.

Because dangerous drug cases can involve multiple legal theories and different filing rules, a defective drug attorney should evaluate the applicable deadline as early as possible.

Waiting for additional lawsuits, regulatory action, or a future recall can result in a claim being filed too late.

How Does a Dangerous Drug Lawsuit Work?

A dangerous drug lawsuit generally begins with an investigation into the medication used, the patient’s injuries, and the conduct of the manufacturer or other potentially responsible parties.

These cases often rely on product liability theories such as defective design, manufacturing defect, and failure to warn, while negligence claims may allege that a manufacturer failed to exercise reasonable care in developing, producing, testing, or warning about a medication.

Dangerous drug claims can also involve recalled drugs, including medications recalled because of newly discovered health risks, manufacturing errors affecting particular batches, safety defects, or incorrect packaging or labeling information.

The legal process may include the following steps:

1. Evaluate the medication and potential claim: Defective drug lawyers review the medication, manufacturer, dates of use, diagnosis, alleged injury, applicable warnings, and filing deadline to determine whether the facts may support a lawsuit for injuries caused by a defective drug.
2. Gather medical and pharmacy records: Medical records, prescription histories, pharmacy records, diagnostic testing, treatment records, and documentation of drug use can help establish exposure, injury, and causation. Documentation and medical evidence are crucial in pharmaceutical liability cases because a plaintiff generally must connect the medication to a specific diagnosed injury.
3. Investigate the drug’s safety and regulatory history: Your legal team may review clinical studies, FDA communications, label changes, adverse-event information, recalls, manufacturing records, and other evidence concerning the medication’s risks. Regulatory compliance can become an important issue when determining what safety information was available, what actions were required, and how the manufacturer responded to emerging evidence.
4. Determine the legal theories and responsible parties: Common legal grounds for dangerous drug lawsuits include failure to warn, defective design, manufacturing defect, negligence, and misrepresentation. Failure-to-warn claims may examine whether the manufacturer adequately disclosed known or reasonably knowable risks, while other claims may focus on whether a drug or particular batch failed to meet applicable safety or manufacturing standards.
5. File the lawsuit and develop the evidence: If the claim is viable, the complaint identifies the defendants, injuries, and legal theories being asserted. During discovery, the parties may obtain medical evidence, corporate documents, internal safety analyses, regulatory records, and testimony addressing what the manufacturer knew about the alleged risks and when it learned that information. Legal precedent involving FDA-approved medications also makes the adequacy and timing of warnings an important issue in many pharmaceutical cases.
6. Proceed individually or through coordinated litigation: Some dangerous drug lawsuits proceed as individual cases, while large numbers of similar federal claims may be coordinated through multidistrict litigation (MDL). MDLs are often used in dangerous drug mass tort litigation to manage shared discovery, expert issues, and other common pretrial matters while each plaintiff retains an individual claim.
7. Resolve the claim through settlement or trial: A case may conclude through an individual settlement, a broader settlement program, mediation, dismissal, or trial. If liability and damages are established, victims may receive compensation for medical expenses, lost wages, pain and suffering, emotional suffering, disability, and other recoverable losses depending on applicable law.

A drug recall can become important evidence, but a recall is not required to bring a defective drug lawsuit, and the existence of a recall does not automatically prove liability.

Whether you can seek the compensation you deserve ultimately depends on the specific medication, injury, scientific evidence, applicable law, and the strength of the evidence connecting the defendant’s conduct to your damages.

What Is Multidistrict Litigation in a Defective Drug Case?

Multidistrict litigation, or MDL, is a federal procedure used to coordinate lawsuits that involve common factual questions, such as claims arising from the same defective drug or alleged pharmaceutical risk.

Instead of combining all plaintiffs into one case, an MDL transfers related federal lawsuits to a single judge for coordinated pretrial proceedings.

This can streamline discovery, expert testimony, motions, and other issues that would otherwise be repeated across hundreds or thousands of individual cases.

Each plaintiff generally keeps an individual claim and must still prove personal drug use, injury, causation, and damages.

Some MDLs use bellwether trials to test representative cases and give the parties information about how juries may respond to recurring evidence and defenses.

If claims are not resolved through settlement or another coordinated process, individual cases may later proceed toward trial.

What Defenses Do Drug Manufacturers Use?

Drug manufacturers may challenge dangerous drug claims by disputing the alleged defect, the adequacy of warnings, product identification, causation, or whether the lawsuit was filed on time.

The available defenses depend on the medication, the legal theory, the patient’s medical history, and the law of the state governing the claim.

Some defenses focus on FDA regulation and prescribing decisions, while others argue that the drug did not cause the plaintiff’s injury.

Common defenses may include:

• Federal preemption: The manufacturer argues that federal law prevented it from independently making the design or labeling change the plaintiff claims was required.
• Adequate warning: The company contends that the drug’s labeling and prescribing information sufficiently disclosed the relevant risks.
• Learned intermediary doctrine: In many states, a manufacturer may argue that it fulfilled its duty by adequately warning the prescribing healthcare professional.
• Lack of product identification: The defendant may dispute whether records establish that the plaintiff actually used its specific medication.
• Alternative causation: The manufacturer may argue that the injury was caused by an underlying medical condition, another medication, genetics, lifestyle factors, or another exposure.
• Misuse or noncompliance: The defense may contend that the patient used the drug contrary to instructions, failed to follow required monitoring, or otherwise used the medication in a way that contributed to the injury.
• Statute of limitations or repose: The defendant may argue that the lawsuit was filed after the applicable legal deadline.
• Insufficient expert evidence: The manufacturer may challenge whether the plaintiff’s medical or scientific experts used reliable methods to establish defect or causation.

Examples of Recent and Current Dangerous Drug Lawsuits

Dangerous drug litigation continues to develop as new scientific evidence, adverse-event information, regulatory actions, and individual injury claims emerge.

Some pharmaceutical lawsuits grow into multidistrict litigation involving thousands of plaintiffs, while others proceed through smaller coordinated proceedings or individual cases.

The allegations and injuries differ substantially by medication, and the existence of a lawsuit does not establish that a drug caused a particular patient’s condition or that a manufacturer is liable.

TorHoerman Law currently provides information on a number of recent and ongoing dangerous drug lawsuits, including:

• Ozempic and GLP-1 Lawsuits: Lawsuits involving Ozempic and other GLP-1 medications allege that manufacturers failed to adequately warn patients about serious gastrointestinal injuries and other complications. Thousands of federal GLP-1 claims are being coordinated in multidistrict litigation.
• Dupixent Lawsuits: Plaintiffs allege that Sanofi and Regeneron failed to adequately warn about a potential association between Dupixent and cutaneous T-cell lymphoma, including mycosis fungoides. Federal cases were consolidated into MDL No. 3180 in June 2026.
• Suboxone Lawsuits: Suboxone lawsuits allege that dissolvable film formulations caused severe tooth decay, enamel erosion, tooth fractures, and other dental injuries and that manufacturers failed to provide adequate warnings. The federal litigation is being coordinated in the Northern District of Ohio.
• Tepezza Lawsuits: Patients allege that Horizon Therapeutics failed to adequately warn about the risk of permanent hearing loss, tinnitus, and other auditory injuries associated with Tepezza. Hundreds of federal claims have been consolidated in multidistrict litigation in the Northern District of Illinois.
• Depo-Provera Lawsuits: Depo-Provera lawsuits allege that Pfizer and related companies failed to adequately warn patients and healthcare providers about an increased risk of meningioma associated with repeated use of the injectable contraceptive. Federal cases were consolidated in the Northern District of Florida, and plaintiffs’ leadership and certain defendants reached an agreement in principle in June 2026 to resolve qualifying claims.

TorHoerman Law: Dangerous and Defective Drug Attorneys

Dangerous drug litigation requires attorneys who understand pharmaceutical science, federal regulation, product liability law, and the procedures used to manage large-scale mass tort cases.

At TorHoerman Law, our attorneys have represented individuals injured by prescription drugs and other pharmaceutical products in nationally coordinated litigation for decades.

Our firm has helped secure more than $4.5 billion in verdicts and negotiated settlements across dangerous drug, product liability, personal injury, and other cases nationwide.

Our pharmaceutical litigation experience includes the $2.4 billion Actos settlement and the $650 million Pradaxa settlement, where Tor Hoerman served in national leadership and Steve Davis was appointed Co-Liaison Counsel in the federal Pradaxa MDL.

Our attorneys have also worked on litigation involving OxyContin, SSRIs, gadolinium contrast agents, AndroGel, and other pharmaceutical products, giving our team experience with the scientific evidence, regulatory issues, discovery, and causation questions that can shape dangerous drug cases.

If you or a family member suffered a serious injury after taking a prescription or over-the-counter medication, we can review the circumstances and determine whether there may be grounds for a dangerous or defective drug claim.

Contact TorHoerman Law for a free initial consultation to discuss your legal options.

Qualifying cases may be handled on a contingency fee basis, meaning you do not pay attorney fees unless we recover compensation for you.

Call TorHoerman Law today or use our chat feature for a no obligation consultation to get started.